Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
CBA Posts Record A$10.98B Profit Despite Cautious Outlook 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Major pharmaceutical companies in South Korea, including Cho Kun Dang, GC Pharma, and Daewoong Pharmaceutical Co., are releasing their own drug for treating COVID-19. The made in Korea medicines are said to be hitting the market soon.
With these South Korean pharma companies’ entrance to the COVID-19 treatment market, Korean drugs for treating the virus just increased to four. This is because Celltrion is also releasing its COVID-19 treatment called the CT-P59 after going through phases of clinical trials.
Drug companies announce successful results of coronavirus treatments
Celltrion was already approved for emergency use in December. This means that South Korea’s Ministry of Food and Drug Safety has given its permission for doctors are to administer Celltrion’s COVID-19 antibody treatment to patients with life-threatening conditions even while clinical trials for CT-P59 or Regdanvimab are still ongoing.
Now, a day after Celltrion reported positive top-line efficacy and safety data from its global Phase II/III clinical trial on Jan. 13, Chong Kun Dang pharma also showed encouraging results from its own phase 2 trial for COVID-19 treatment called Nafamostat.
This drug has been tested on more than 100 volunteers in Russia. At least 36 high-risk patients were given the drug, and Nafamostat reportedly showed 61.1% clinical improvement. Plus, just like what Celltrion claimed, Chong Kun Dang also stated that its COVID-19 treatment drug shortened the recovery time of patients by at least four days.
Chong Kun Dang further suggests that Nafamostat can help prevent death in seriously-ill COVID-19 patients. As per the Korea Herald, the pharmaceutical firm is now trying to get approval for its phase 3 trials and emergency use.
Emergency-use drug application for the pharma companies
Celltrion was already approved for emergency use, and Ching Kung Dang sent its application for approval. On the other hand, GC Pharma and Daewoong are also expected to apply soon.
For GC Pharma, it will get approval for its blood plasma-derived COVID-19 treatment called GC5131A. It has completed its phase 2 trial with 60 volunteers, and data results are expected to come out soon. This company’s drug is meant to treat patients of serious COVID-19 cases.
Daewoong is now in phase 3 trial, but although its phase 2 tests returned good results, it did not show the effects they were hoping for. It will be applying for emergency use authorization for its Camostat drug that is meant for treating mild and moderate cases.
Finally, all of these companies still need to show more results from phase 3 trials so they can be approved and eventually released into the market.
